KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Investment Securities (2016 - 2026)

Biomarin Pharmaceutical's Gains from Investment Securities history spans 17 years, with the latest figure at -$51.1 million for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 136.24% year-over-year to -$51.1 million, compared with a TTM value of -$21.4 million through Sep 2025, down 1805.66%, and an annual FY2024 reading of -$20.1 million, changed N/A over the prior year.
  • Gains from Investment Securities for Q3 2025 was -$51.1 million at Biomarin Pharmaceutical, down from $49.8 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $49.8 million in Q2 2025, with the low at -$51.1 million in Q3 2025.
  • Average Gains from Investment Securities over 5 years is -$1.1 million, with a median of $247000.0 recorded in 2023.
  • Biggest YoY gain for Gains from Investment Securities was 3604.83% in 2024; the steepest drop was 1222.69% in 2024.
  • Tracing BMRN's Gains from Investment Securities over 5 years: stood at -$1.3 million in 2021, then soared by 1021.79% to $12.1 million in 2022, then tumbled by 113.47% to -$1.6 million in 2023, then plummeted by 1208.2% to -$21.4 million in 2024, then plummeted by 138.86% to -$51.1 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Gains from Investment Securities are -$51.1 million (Q3 2025), $49.8 million (Q2 2025), and $1.3 million (Q1 2025).